News Releases

Archives: Search / 2018 / 2017 / 2016 / 2015 / 2014 / 2013 / 2012

201120102009200820072003

2014 Archives

Dec 11, 2014
-- Findings Presented at 2014 San Antonio Breast Cancer Symposium (SABCS) --

Nektar Therapeutics (NASDAQ: NKTR) today presented biomarker data from a sub-study of the Phase 3 BEACON study of etirinotecan pegol (NKTR-102) which collected and analyzed circulating tumor cell...

More
Dec 9, 2014
First-in-class treatment approved for adult patients with opioid-induced constipation who have had an inadequate response to laxatives

Nektar Therapeutics (NASDAQ:NKTR) reported partner AstraZeneca today announced that MOVENTIG® (naloxegol) has been granted Marketing Authorisation by the European Commission (EC) for the...

More
Dec 1, 2014
Twice-Weekly Prophylactic Regimen Resulted in 95% Reduction in Median Annualized Bleed Rate Compared to On-Demand Treatment

Nektar Therapeutics (NASDAQ:NKTR) reported that partner Baxter International Inc. today announced that the company has submitted a biologics license application (BLA) to the United States Food and...

More
Nov 24, 2014

Whippany, N.J., November 24, 2014 – The U.S. Food and Drug Administration (FDA) has granted qualified infectious disease product (QIDP) designation to two Bayer investigational agents,...

More
Nov 20, 2014

Nektar Therapeutics (NASDAQ: NKTR) today announced results of a study investigating the preclinical anti-tumor activity and tolerability of etirinotecan pegol (NKTR-102) in combination with the...

More
Nov 6, 2014

Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the third quarter ended September 30, 2014. Cash and investments in marketable securities at September 30, 2014 were...

More
Oct 30, 2014

Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter ended September 30, 2014 on Thursday, November 6, 2014, after the close of U.S.-based financial...

More
Sep 26, 2014

AstraZeneca today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of MOVENTIG®...

More
Sep 19, 2014

Nektar Therapeutics (NASDAQ:NKTR) today announced results from preclinical studies characterizing the analgesic profiles of a series of the company's internally-discovered oral,...

More
Sep 16, 2014

AstraZeneca (NYSE: AZN) today announced that the US Food and Drug Administration (FDA) approved MOVANTIK™ (naloxegol) Tablets C-II as the first once-daily oral peripherally-acting mu-opioid...

More
Aug 21, 2014
Twice-Weekly Prophylactic Regimen Resulted in 95% Reduction in Median Annualized Bleed Rate Compared to On-Demand

Nektar Therapeutics (NASDAQ: NKTR) reports Baxter International Inc. today announced positive results from its Phase 3 pivotal clinical trial of BAX 855, an investigational, extended half-life...

More
Jul 31, 2014

Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the second quarter ended June 30, 2014. Cash and investments in marketable securities at June 30, 2014 were $301.4...

More
Jul 22, 2014

Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter ended June 30, 2014 on Thursday, July 31, 2014, after the close of U.S.-based financial markets....

More
Jun 19, 2014

Nektar Therapeutics (NASDAQ:NKTR) reported that partner AstraZeneca today announced that the New England Journal of Medicine (NEJM) has published results of two pivotal Phase III studies –...

More
Jun 12, 2014

Nektar Therapeutics (NASDAQ:NKTR) reported today that partner AstraZeneca announced that the majority of US Food and Drug Administration (FDA) Anesthetic and Analgesic Drug Products Advisory...

More
Jun 11, 2014

Nektar Therapeutics (NASDAQ:NKTR), a biopharmaceutical company developing novel pain and cancer therapeutics, today announced that NASDAQ has halted trading of the company's common stock. The U.S....

More
Jun 1, 2014
NKTR-214 combined with anti-PD-1 or anti-CTLA-4 provides significant tumor growth inhibition in both EMT6 breast and CT26 colon tumor models

Nektar Therapeutics (NASDAQ:NKTR) announced positive preclinical data for NKTR-214, a new investigational cancer immunotherapy which selectively activates the IL-2 receptor complex and is being...

More
May 31, 2014
Single agent NKTR-102 exceeds primary endpoint with fifty-five percent of patients achieving six-week progression-free survival and fifteen percent of patients achieving partial response

Nektar Therapeutics (NASDAQ: NKTR) announced today new data from an investigator-sponsored Phase 2 study of NKTR-102 (etirinotecan pegol) in patients with Avastin-refractory high-grade glioma...

More
May 19, 2014

Nektar Therapeutics (Nasdaq: NKTR), a biopharmaceutical company developing novel pain and cancer therapeutics, announced that Ivan Gergel, M.D., will serve as the Company's new Senior Vice...

More
May 16, 2014

Nektar Therapeutics' (Nasdaq: NKTR) is scheduled to present at the upcoming UBS 2014 Global Healthcare Conference in New York at the Sheraton New York Hotel on Tuesday, May 20, 2014 at 2:30 p.m....

More
May 7, 2014

Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the first quarter ended March 31, 2014. Cash and investments in marketable securities at March 31, 2014 were $309.1...

More
May 1, 2014

Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter ended March 31, 2014 on Wednesday, May 7, 2014, after the close of U.S.-based financial markets. Howard...

More
Apr 9, 2014

Nektar Therapeutics (Nasdaq: NKTR), a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technologies, today announced that...

More
Feb 26, 2014

Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the fourth quarter and year ended December 31, 2013. Cash and investments in marketable securities at December 31, 2013 were

More
Feb 19, 2014

Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the fourth quarter and year-ended December 31, 2013 on Wednesday, February 26, 2014, after the close of U.S.-based...

More
 

print email rss
 
 
Site Map Privacy Terms of Use Compliance Policy Trademarks Site Users Guide